Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Julphar
Federal Trade Commission
Argus Health
Cantor Fitzgerald
Farmers Insurance

Generated: August 25, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,926,357

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,926,357
Title:BMP-7 peptides and methods of use
Abstract: The invention relates to truncated BMP-7 growth factors and variants thereof. The invention also relates to methods of making and using the truncated BMP-7 growth factors.
Inventor(s): Qin; Xiaofei (Virginia Beach, VA), Chen; Silvia (Virginia Beach, VA), Chen; Jingsong (Virginia Beach, VA), Clagett; James (Virginia Beach, VA)
Assignee: LifeNet Health (Virginia Beach, VA)
Application Number:13/636,869
Patent Claims:1. A composition comprising at least one pharmaceutically acceptable carrier, at least one protease that is not bone morphogenetic protein-1 (BMP-1) or a cysteine protease, and a peptide consisting of the amino acid sequence of SEQ ID NO: 3, wherein the peptide has osteoinductive activity or chondroinductive activity.

2. A composition comprising at least one pharmaceutically acceptable carrier, at least one protease that is not bone morphogenetic protein-1 (BMP-1) or a cysteine protease, and a peptide consisting of the amino acid sequence of SEQ ID NO: 3, wherein the peptide has osteoinductive activity or chondroinductive activity, and wherein the molar ratio of the at least one protease to the peptide is between 1:1000 and 1000:1.

3. The composition according to claim 1, wherein the at least one protease is selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof.

4. The composition according to claim 1, wherein the concentration of the peptide is between 10 ng/mL and 200 ng/mL.

5. The composition according to claim 1, wherein the concentration of the peptide is between 10 ng/mL and 100 ng/mL.

6. The composition according to claim 1, wherein the concentration of the peptide is between 10 ng/mL and 50 ng/mL.

7. The composition according to claim 1, wherein the concentration of the peptide is between 10 ng/mL and 25 ng/mL.

8. The composition according to claim 1, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, dextrose solution, 5% human serum albumin, dispersion media, coatings, antibacterial and antifungal agents, and isotonic and absorption delaying agents.

9. A composition comprising a pharmaceutically acceptable carrier and a peptide consisting of the amino acid sequence of SEQ ID NO: 3.

10. A method of promoting differentiation of cells into osteoblasts or chondrocytes, the method comprising treating the cells with the composition of claim 1 in an amount effective to promote the differentiation, wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells.

11. The method of claim 10, wherein the cells are progenitor cells or adult stem cells.

12. The method of claim 11, wherein the progenitor cells or the adult stem cells are derived from placenta, bone marrow, adipose tissue, blood vessel, amniotic fluid, synovial fluid, synovial membrane, pericardium, periosteum, dura, peripheral blood, umbilical blood, menstrual blood, baby teeth, nucleus pulposus, brain, skin, hair follicle, intestinal crypt, neural tissue, or muscle.

13. The method of claim 10, wherein the cells are induced pluripotent stem cells.

14. A method of promoting osteogenesis in a tissue, the method comprising treating the tissue with the composition of claim 1 in an amount effective to promote the osteogenesis in the tissue, wherein the tissue is a bone tissue.

15. The method of claim 14, wherein the osteogenic activity of cells in the treated tissue is greater than the osteogenic activity of cells in untreated tissue.

16. A method of increasing a cellular growth factor activity in cells, the method comprising treating the cells with the composition of claim 1 in an amount effective to increase the cellular growth factor activity in the cells, wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells, and wherein the cellular growth factor activity is osteoinductive activity, chondroinductive activity, or a combination thereof.

17. The method according to claim 16, wherein the cells are progenitor cells or adult stem cells.

18. The method according to claim 17, wherein the progenitor cells or the adult stem cells are derived from placenta, bone marrow, adipose tissue, blood vessel, amniotic fluid, synovial fluid, synovial membrane, pericardium, periosteum, dura, peripheral blood, umbilical blood, menstrual blood, baby teeth, nucleus pulposus, brain, skin, hair follicle, intestinal crypt, neural tissue, or muscle.

19. The method according to claim 16, wherein the cells are induced pluripotent stem cells.

20. The method according to claim 16, wherein the at least one protease comprises two or more proteases.

21. The method according to claim 20, wherein the two or more proteases comprise: (a) a first protease selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof, and (b) a second protease selected from the group consisting of collagenase, clostripain, dispase, trypsin, MMP-13 (matrix metalloproteinase-13), and a mixture thereof, and wherein the first and second proteases are different.

22. The method according to claim 16, wherein the at least one protease is collagenase.

23. A method of increasing a cellular growth factor activity in cells, the method comprising treating the cells with the composition of claim 9, wherein the cells are progenitor cells, adult stem cells, or induced pluripotent stem cells, and wherein the cellular growth factor activity is osteoinductive activity, chondroinductive activity, or a combination thereof.

24. A method of growing and/or culturing cells comprising growing and/or culturing cells in vitro in the presence of the composition of claim 1.

25. The method according to claim 24, wherein the cells are selected from the group consisting of mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells, progenitor cells, differentiated cells, undifferentiated cells, and induced pluripotent stem cells.

26. A method of making the composition of claim 1, comprising preparing said peptide by contacting mature BMP-7 with collagenase under conditions that promote protein cleavage to produce the peptide and harvesting the peptide, and mixing the peptide with the at least one pharmaceutically acceptable carrier and the at least one protease, whereby the composition of claim 1 is prepared.

27. A method of making the composition of claim 1, comprising preparing said peptide by culturing a host cell under conditions suitable for protein expression, wherein the host cell comprises a vector that encodes said peptide, harvesting the peptide, and mixing the peptide with the at least one pharmaceutically acceptable carrier and the at least one protease, whereby the composition of claim 1 is prepared.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledMarch 24, 2011PCT Application Number:PCT/US2011/029794
PCT Publication Date:September 29, 2011PCT Publication Number:WO2011/119833

Details for Patent 9,926,357

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Try a Free Trial LifeNet Health (Virginia Beach, VA) 2030-03-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
McKinsey
Express Scripts
Johnson and Johnson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.